Literature DB >> 31727837

Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy.

Cristina Gil-Cruz1, Christian Perez-Shibayama1, Angelina De Martin1, Francesca Ronchi2, Katrien van der Borght3, Rebekka Niederer1, Lucas Onder1, Mechthild Lütge1, Mario Novkovic1, Veronika Nindl1, Gustavo Ramos4,5, Markus Arnoldini6, Emma M C Slack6, Valérie Boivin-Jahns5,7, Roland Jahns5,8, Madeleine Wyss9, Catherine Mooser2, Bart N Lambrecht3, Micha T Maeder10, Hans Rickli10, Lukas Flatz1, Urs Eriksson11,12, Markus B Geuking13, Kathy D McCoy9, Burkhard Ludewig14.   

Abstract

Myocarditis can develop into inflammatory cardiomyopathy through chronic stimulation of myosin heavy chain 6-specific T helper (TH)1 and TH17 cells. However, mechanisms governing the cardiotoxicity programming of heart-specific T cells have remained elusive. Using a mouse model of spontaneous autoimmune myocarditis, we show that progression of myocarditis to lethal heart disease depends on cardiac myosin-specific TH17 cells imprinted in the intestine by a commensal Bacteroides species peptide mimic. Both the successful prevention of lethal disease in mice by antibiotic therapy and the significantly elevated Bacteroides-specific CD4+ T cell and B cell responses observed in human myocarditis patients suggest that mimic peptides from commensal bacteria can promote inflammatory cardiomyopathy in genetically susceptible individuals. The ability to restrain cardiotoxic T cells through manipulation of the microbiome thereby transforms inflammatory cardiomyopathy into a targetable disease.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31727837     DOI: 10.1126/science.aav3487

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  57 in total

1.  Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?

Authors:  B Brett Finlay; Romina Goldszmid; Kenya Honda; Giorgio Trinchieri; Jennifer Wargo; Laurence Zitvogel
Journal:  Nat Rev Immunol       Date:  2020-07-13       Impact factor: 53.106

Review 2.  Host-microbiota interactions in immune-mediated diseases.

Authors:  William E Ruff; Teri M Greiling; Martin A Kriegel
Journal:  Nat Rev Microbiol       Date:  2020-05-26       Impact factor: 60.633

Review 3.  A cardioimmunologist's toolkit: genetic tools to dissect immune cells in cardiac disease.

Authors:  Anthony Wong; Homaira Hamidzada; Slava Epelman
Journal:  Nat Rev Cardiol       Date:  2022-05-06       Impact factor: 32.419

Review 4.  Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review.

Authors:  Taylor Halsey; Gabriel Ologun; Jennifer Wargo; Robert R Jenq
Journal:  Semin Hematol       Date:  2020-05-19       Impact factor: 3.851

Review 5.  Adding insult to injury - Inflammation at the heart of cardiac fibrosis.

Authors:  Sasha Smolgovsky; Udoka Ibeh; Tatiana Peña Tamayo; Pilar Alcaide
Journal:  Cell Signal       Date:  2020-11-06       Impact factor: 4.315

Review 6.  Microbial modulation of intestinal T helper cell responses and implications for disease and therapy.

Authors:  Markus B Geuking; Regula Burkhard
Journal:  Mucosal Immunol       Date:  2020-08-13       Impact factor: 7.313

Review 7.  The microbiome and human cancer.

Authors:  Gregory D Sepich-Poore; Laurence Zitvogel; Ravid Straussman; Jeff Hasty; Jennifer A Wargo; Rob Knight
Journal:  Science       Date:  2021-03-26       Impact factor: 47.728

Review 8.  Sequence meets function-microbiota and cardiovascular disease.

Authors:  Myungsuk Kim; Md Nazmul Huda; Brian J Bennett
Journal:  Cardiovasc Res       Date:  2022-01-29       Impact factor: 10.787

Review 9.  Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.

Authors:  Javid Moslehi; Andrew H Lichtman; Arlene H Sharpe; Lorenzo Galluzzi; Richard N Kitsis
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

Review 10.  Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review.

Authors:  Petra Mamic; Thanat Chaikijurajai; W H Wilson Tang
Journal:  J Mol Cell Cardiol       Date:  2020-12-09       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.